Phase 2 clinical trials showed meaningful clinical benefits of FGFR inhibitors in the treatment of chemorefractory iCCA patients carrying FGFR2 fusions, which constitute the most clinically responsive group of patients. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.